Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Withdrawn 1Completed 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × tebentafusp × Dermatologic × Clear all
NCT02535078 2024-07-24

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Immunocore Ltd

Phase 1/2 Withdrawn
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡